SWITCH FROM ETANERCEPT ORIGINATOR TO ETANERCEPT BIOSIMILAR: DATA FROM REAL LIFE

被引：0
|
作者：
Ditto, Maria Chiara [1 ]
Parisi, Simone [1 ]
Priora, Marta [1 ]
Lagana, Angela [1 ]
Peroni, Clara Lisa [1 ]
Fusaro, Enrico [1 ]
机构：
[1] Citta Salute & Sci Torino, Rheumatol Unit, Turin, Italy
来源：
ANNALS OF THE RHEUMATIC DISEASES | 2019年 / 78卷
关键词：
D O I：
10.1136/annrheumdis-2019-eular.7809
中图分类号：
R5 [内科学];
学科分类号：
1002 ; 100201 ;
摘要：
AB0401
引用
收藏
页码：1661 / 1661
页数：1
相关论文
共 50 条
  • [1] Efficacy and safety of a single switch from etanercept originator to etanercept biosimilar in a cohort of inflammatory arthritis
    Maria Chiara Ditto
    Simone Parisi
    Marta Priora
    Silvia Sanna
    Clara Lisa Peroni
    Angela Laganà
    Antonio D’Avolio
    Enrico Fusaro
    [J]. Scientific Reports, 10
  • [2] Efficacy and safety of a single switch from etanercept originator to etanercept biosimilar in a cohort of inflammatory arthritis
    Ditto, Maria Chiara
    Parisi, Simone
    Priora, Marta
    Sanna, Silvia
    Peroni, Clara Lisa
    Lagana, Angela
    D'Avolio, Antonio
    Fusaro, Enrico
    [J]. SCIENTIFIC REPORTS, 2020, 10 (01)
  • [3] ANALYSIS OF RHEUMATOID ARTHRITIS PATIENTS WHO FAILED THE SWITCH FROM ORIGINATOR ETANERCEPT TO BIOSIMILAR ETANERCEPT IN CROYDON
    Patel, Dimil
    Ahmed, Tazeen J.
    Levy, Sarah
    Rajak, Rizwan
    Sathananthan, Rosh
    Horwood, Natalie
    [J]. RHEUMATOLOGY, 2018, 57
  • [4] Incidence of and Reasons and Determinants Associated with Retransitioning from Biosimilar Etanercept to Originator Etanercept
    Rosanne W. Meijboom
    Helga Gardarsdottir
    Matthijs L. Becker
    Saskia ten Wolde
    Toine C. G. Egberts
    Thijs J. Giezen
    [J]. BioDrugs, 2021, 35 : 765 - 772
  • [5] Incidence of and Reasons and Determinants Associated with Retransitioning from Biosimilar Etanercept to Originator Etanercept
    Meijboom, Rosanne W.
    Gardarsdottir, Helga
    Becker, Matthijs L.
    ten Wolde, Saskia
    Egberts, Toine C. G.
    Giezen, Thijs J.
    [J]. BIODRUGS, 2021, 35 (06) : 765 - 772
  • [6] Biosimilar versus originator etanercept: a real-life clinical study
    Giordano, Domenico
    Capalbo, Alessandro
    Gagliostro, Nazareno
    Fedele, Giusy
    Balampanos, Charalampos G.
    Persechino, Flavia
    Bushati, Vilma
    Ulisse, Salvatore
    Persechino, Severino
    Pellacani, Giovanni
    [J]. ITALIAN JOURNAL OF DERMATOLOGY AND VENEREOLOGY, 2022, 157 (04) : 318 - 324
  • [7] FREQUENCY AND REASONS FOR SWITCHING BACK TO ETANERCEPT ORIGINATOR FOLLOWING INITIAL SWITCH TO ETANERCEPT BIOSIMILAR
    Davies, Rebecca
    Kearsley-Fleet, Lianne
    Lunt, Mark
    Watson, Kath D.
    Hyrich, Kimme L.
    [J]. RHEUMATOLOGY, 2019, 58
  • [8] Efficacy and Safety of Biosimilar and Originator Etanercept in Rheumatoid Arthritis Patients: Real-Life Data
    Atzeni, Fabiola
    Gerratana, Elisabetta
    Bongiovanni, Sara
    Talotta, Rossella
    Miceli, Gianfranco
    Salaffi, Fausto
    Sarzi-Puttini, Piercarlo
    [J]. ISRAEL MEDICAL ASSOCIATION JOURNAL, 2021, 23 (06): : 344 - 349
  • [9] SAFETY AND RETENTION RATE AFTER SWITCHING FROM ETANERCEPT ORIGINATOR (ETN) TO ETANERCEPT BIOSIMILAR (SB4) IN INFLAMMATORY JOINT DISEASES: DATA FROM REAL LIFE.
    Bruni, C.
    Gentileschi, S.
    Capassoni, M.
    Pacini, G.
    Bardelli, M.
    Baldi, C.
    Tofani, L.
    Cometi, L.
    Nacci, F.
    Bartoli, F.
    Fiori, G.
    Cantarini, L.
    Guiducci, S.
    Frediani, B.
    Matucci-Cerinic, M.
    [J]. ANNALS OF THE RHEUMATIC DISEASES, 2020, 79 : 1435 - 1436
  • [10] Acceptance Rate and Sociological Factors Involved in the Switch from Originator to Biosimilar Etanercept (SB4)
    Scherlinger, Marc
    Germain, Vincent
    Langlois, Emmanuel
    Schaeverbeke, Thierry
    [J]. ARTHRITIS & RHEUMATOLOGY, 2018, 70
12345